Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Mar 1;7(9):10023-36.
doi: 10.18632/oncotarget.7054.

CD133 expression may be useful as a prognostic indicator in colorectal cancer, a tool for optimizing therapy and supportive evidence for the cancer stem cell hypothesis: a meta-analysis

Yang Zhao  1   2 , Jing Peng  1 , Enlong Zhang  1 , Ning Jiang  2 , Jiang Li  1 , Qi Zhang  1 , Xuening Zhang  1 , Yuanjie Niu  2
Affiliations
Meta-Analysis

CD133 expression may be useful as a prognostic indicator in colorectal cancer, a tool for optimizing therapy and supportive evidence for the cancer stem cell hypothesis: a meta-analysis

Yang Zhao et al. Oncotarget. .

Abstract

We performed a meta-analysis of CD133-related clinical data to investigate the role of cancer stem cells (CSCs) in the clinical outcomes of colorectal cancer (CRC) patients, analyzing the effectiveness of various therapeutic strategies and examining the validity of the CSC hypothesis. For 28 studies (4546 patients), the relative risk (RR) to survival outcomes associated with CD133+ CRCs were calculated using STATA 12.0 software. Pooled results showed that CD133High patients had poor 5-year overall survival (RR 0.713, 95% CI 0·616-0·826) and 5-year disease free survival (RR 0·707, 95% CI 0·602-0·831). Both associations were consistently observed across different races, research techniques and therapeutic strategies. In a subgroup receiving adjuvant therapy, CD133Low patients achieved significantly better survival than CD133High patients. The findings suggest that CD133 could serve as a predictive marker of poor prognosis and treatment failure in CRC. CD133Low patients could benefit from adjuvant treatments, while CD133High patients should be given novel treatments besides adjuvant therapy. Our results also provide evidence in support of the CSC hypothesis.

Keywords: CD133; cancer stem cell; meta-analysis; tumor genesis; tumor recurrence.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

All authors declared that they had no conflicts of interests.

Figures

Figure 1
Figure 1. Flow chart for eligible articles identified in this meta-analysis
Figure 2
Figure 2
Begg's funnel plots to explore the possibility of publication bias in the pooled analyses of CD133 expression and OS (A) or DFS (B).
Figure 3
Figure 3. Forest plots of RRs for the association of CD133 expression with the (A) OS and (B) DFS
Figure 4
Figure 4. The stratified analysis evaluating the association of CD133 expression with (A) OS and (B) DFS in the subgroups with or without AT
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–111. - PubMed
    1. Nguyen LV, Vanner R, Dirks P, Eaves CJ. Cancer stem cells: an evolving concept. Nat Rev Cancer. 2012;12:133–143. - PubMed
    1. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM. Cancer stem cells—perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006;66:9339–9344. - PubMed
    1. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med. 2011;17:313–319. - PubMed
    1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983–3988. - PMC - PubMed

Publication types

MeSH terms